BNP Paribas Acquires 7,218 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

BNP Paribas lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1,031.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,918 shares of the company’s stock after purchasing an additional 7,218 shares during the period. BNP Paribas’ holdings in Teva Pharmaceutical Industries were worth $143,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. FMR LLC increased its stake in shares of Teva Pharmaceutical Industries by 49.5% in the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after purchasing an additional 20,762,226 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Teva Pharmaceutical Industries by 6.8% in the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after purchasing an additional 2,204,623 shares during the period. Renaissance Technologies LLC increased its stake in shares of Teva Pharmaceutical Industries by 13.4% in the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock worth $141,839,000 after purchasing an additional 1,031,400 shares during the period. Truist Financial Corp increased its stake in Teva Pharmaceutical Industries by 7.0% during the second quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock valued at $63,135,000 after acquiring an additional 254,483 shares during the period. Finally, Swiss National Bank increased its stake in Teva Pharmaceutical Industries by 0.5% during the third quarter. Swiss National Bank now owns 3,342,900 shares of the company’s stock valued at $60,239,000 after acquiring an additional 15,300 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TEVA. UBS Group boosted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Barclays boosted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Down 0.1 %

NYSE TEVA opened at $16.57 on Thursday. The company has a market capitalization of $18.77 billion, a price-to-earnings ratio of -19.49, a PEG ratio of 1.30 and a beta of 0.87. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a 1-year low of $9.35 and a 1-year high of $19.31. The stock’s 50 day moving average is $17.60 and its two-hundred day moving average is $17.35.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.